{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:32:35Z","timestamp":1778049155830,"version":"3.51.4"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Visceral leishmaniasis (VL) is one of the important parasitic diseases, with approximately 350 million people at risk. Due to the nonavailability of an ideal drug, development of a safe, effective, and affordable vaccine could be a solution for control and prevention of this disease. The present study was carried out to examine the immunological potential of kinesin protein from the microtubule locus of<jats:italic>Leishmania donovani<\/jats:italic>as a suitable vaccine candidate. In silico analysis of this region revealed clusters of major histocompatibility complex class I and II binding epitopes in its motor domain region. A recombinant protein was expressed from this region and named rLvacc. The antigenicity and immunogenicity studies of this protein by Western blot analysis revealed that rLvacc is strongly recognized by sera from acute VL patients. To evaluate its immunogenicity, peripheral blood mononuclear cells from cured VL patients were separated, and a lymphocyte proliferation assay was carried out in the presence of rLvacc. After lymphocyte proliferation, the pooled culture supernatant was assayed for anti-rLvacc antibody titers using an enzyme-linked immunosorbent assay. The results showed that immunoglobulin G2 (IgG2) subtype antibodies were predominant, while IgG1 subtype antibodies were produced in very low titers. On the basis of these ex vivo preliminary findings, its immunogenicity was studied in BALB\/c mice. Vaccination with the DNA construct generated a good cellular immune response with significant increases in gamma interferon and interleukin-2 (IL-2) cytokine levels (Th1), but no increase in IL-4 levels (Th2). Taken together, our findings suggest the kinesin motor domain region of<jats:italic>L. donovani<\/jats:italic>as a potential vaccine candidate against visceral leishmaniasis.<\/jats:p>","DOI":"10.1128\/cvi.00433-07","type":"journal-article","created":{"date-parts":[[2008,3,20]],"date-time":"2008-03-20T00:55:09Z","timestamp":1205974509000},"page":"836-842","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Kinesin Motor Domain of<i>Leishmania donovani<\/i>as a Future Vaccine Candidate"],"prefix":"10.1128","volume":"15","author":[{"given":"Ayan","family":"Dey","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi 110029, India"},{"name":"Immunology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawan","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi 110029, India"},{"name":"Immunology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh Singh","family":"Redhu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi 110029, India"},{"name":"Immunology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarman","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi 110029, India"},{"name":"Immunology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-308X(08)60152-9","volume":"42","year":"1999","unstructured":"Alarcon, J. B., G. W. Waine, and D. P. McManus. 1999. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv. Parasitol.42:343-410.","journal-title":"Adv. Parasitol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","volume":"174","year":"2005","unstructured":"Basu, R., S. Bhaumik, J. M. Basu, K. Naskar, T. De, and S. Roy. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol.174:7160-7171.","journal-title":"J. Immunol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1073\/pnas.90.2.775","volume":"90","year":"1993","unstructured":"Burns, J. M., Jr., W. G. Shreffler, D. R. Benson, H. W. Ghalib, R. Badaro, and S. G. Reed. 1993. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral Leishmaniasis. Proc. Natl. Acad. Sci. USA90:775-779.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI112209","volume":"76","year":"1985","unstructured":"Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson. 1985. Absence of gamma-interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Investig.76:2066-2069.","journal-title":"J. Clin. Investig."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/infdis\/168.4.986","volume":"168","year":"1993","unstructured":"Cenini, P., N. Berhe, A. Hailu, K. McGinnes, and D. Frommel. 1993. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis.168:986-993.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-9292-1-1","volume":"1","year":"2002","unstructured":"Chang, K. P., and B. S. McGwire. 2002. Molecular determinants and regulation of Leishmania virulence. Kinetoplastid Biol. Dis.1:1-7.","journal-title":"Kinetoplastid Biol. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.140.8.2721","volume":"140","year":"1988","unstructured":"Cillari, E., F. Y. Liew, P. L. Campo, S. Milano, S. Mansueto, and A. Salerno. 1988. Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J. Immunol.140:2721-2726.","journal-title":"J. Immunol."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.8.4215-4225.2002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00394-07"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2249.2005.02745.x","volume":"140","year":"2005","unstructured":"Garg, R., S. K. Gupta, P. Tripathi, S. Naik, S. Sundar, and A. Dube. 2005. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol.140:149-156.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1471-4922(03)00139-9","volume":"19","year":"2003","unstructured":"Garraud, O., R. Perraut, G. Riveau, and T. B. Nutman. 2003. Class and subclass selection in parasite-specific antibody responses. Trends Parasitol.19:300-304.","journal-title":"Trends Parasitol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1172\/JCI116570","volume":"92","year":"1993","unstructured":"Ghalib, H. W., M. R. Piuvezam, Y. A. W. Skeiky, M. Siddiq, F. A. Hashim, A. M. El-Hassan, D. M. Russo, and S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Investig.92:324-329.","journal-title":"J. Clin. Investig."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","volume":"20","year":"2001","unstructured":"Ghosh, A., W. W. Zhang, and G. Matlashewski. 2001. Immunization with A2 protein results in mixed Th1\/Th2 and a humoral response which protects against Leishmania donovani infections. Vaccine20:59-66.","journal-title":"Vaccine"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","volume":"186","year":"1997","unstructured":"Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glachenhaus, and R. A. Seader. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with L. major. J. Exp. Med.186:1137-1147.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.42.2.702-707.1983"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","volume":"354","year":"1999","unstructured":"Herwaldt, B. L. 1999. Leishmaniasis. Lancet354:1191-1199.","journal-title":"Lancet"},{"key":"e_1_3_2_18_2","first-page":"207","volume":"51","year":"1983","unstructured":"Ho, M., D. K. Koech, D. W. Iha, and A. D. M. Bryceson. 1983. Immunosuppression in Kenyan visceral leishmaniasis. Clin. Exp. Immunol.51:207-214.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_2_19_2","first-page":"4696","volume":"6","year":"2004","unstructured":"Iwai, S., A. Ishiji, I. Mabuchi, and K. A. Sutoh. 2004. Novel actin-bundling kinesin-related protein from Dictyostelium discoideum. J. Biol. Chem.6:4696-4704.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI116372","volume":"91","year":"1993","unstructured":"Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. Satti, A. M. Kordofani, F. A. Hashim, H. A. Mohammed, A. N. Franklin, N. B. Thomas, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-\u03b3. J. Clin. Investig.91:1644-1648.","journal-title":"J. Clin. Investig."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.4049\/jimmunol.153.11.4948","volume":"153","year":"1994","unstructured":"Kawano, Y., T. Noma, and J. Yata. 1994. Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J. Immunol.153:4948-4958.","journal-title":"J. Immunol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.3.1069-1073.1993"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","year":"1983","unstructured":"Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. lmmunol. Methods65:55-63.","journal-title":"J. lmmunol. Methods"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1084\/jem.189.4.741","volume":"189","year":"1999","unstructured":"Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med.189:741-746.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-3083.2005.01686.x","volume":"62","year":"2005","unstructured":"Peruhype-Magalh\u00e3es, V., O. A. Martins-Filho, A. Prata, A. Silva Lde, A. Rabello, A. Teixeira-Carvalho, R. M. Figueiredo, S. F. Guimar\u00e3es-Carvalho, T. C. Ferrari, and R. Correa-Oliveira. 2005. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand. J. Immunol.62:487-495.","journal-title":"Scand. J. Immunol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.4049\/jimmunol.147.10.3575","volume":"147","year":"1991","unstructured":"Russo, D. M., J. M. Burns, Jr., E. M. Carvalho, R. J. Armitage, K. H. Grabstein, L. L. Button, W. R. Mcmaster, and S. G. Reed. 1991. Human T cell responses to gp63, a surface antigen of Leishmania. J. Immunol.147:3575-3580.","journal-title":"J. Immunol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199907223410410","volume":"341","year":"1999","unstructured":"Seder, R. A., and S. Gurunathan. 1999. DNA vaccines: designer vaccines for the 21st century. N. Engl. J. Med.341:277-278.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/bioinformatics\/17.12.1236","volume":"17","year":"2001","unstructured":"Singh, H., and G. P. S. Raghava. 2001. ProPred: prediction of HLA-DR binding sites. Bioinformatics17:1236-1237.","journal-title":"Bioinformatics"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pep.2005.07.027","volume":"46","year":"2006","unstructured":"Sivakumar, R., P. Sharma, K. P. Chang, and S. Singh. 2006. Cloning, expression and purification of a novel recombinant antigen Leishmania donovani. Protein Expr. Purif.46:156-165.","journal-title":"Protein Expr. Purif."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","volume":"165","year":"2000","unstructured":"Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol.165:7064-7071.","journal-title":"J. Immunol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0264-410X(02)00352-3","volume":"21","year":"2003","unstructured":"Sukumaran, B., P. Tewary, S. Saxena, and R. Madhubala. 2003. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine21:1292-1299.","journal-title":"Vaccine"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0090-1229(90)90038-R","volume":"57","year":"1990","unstructured":"Zwingenberger, K., G. Harms, C. Pedrosa, S. Omena, B. Sandkamp, and S. K. Neifer. 1990. Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-\u03b3 production. Clin. Immunol. Immunopathol.57:242-249.","journal-title":"Clin. Immunol. Immunopathol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00433-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00433-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T23:14:54Z","timestamp":1708730094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00433-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1128\/CVI.00433-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00433-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"2007-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}